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Because opiate analgesics are highly addictive substances, their use in the treatment of chronic nonmalig-
nant pain remains controversial.Opiates have been used for centuries and
remain to this day the most potent and
reliable analgesic agents (Pasternak,
2011). They are used routinely and effec-
tively for the treatment of acute severe
pain following trauma, extensive burns,
or surgery. They are also used for patients
with painful terminal diseases such as
cancer. In these time-limited situations,
the efficacy of opiates is extensively
documented and broadly accepted. In
fact, their use has recently grown, in part
because providing adequate pain relief
is now considered an important standard
of care and is required by law in some
states. Beyond potent analgesia, opiates
reduce anxiety and producemild sedation
and a palpable sense of well-being, often
to the point of euphoria. These are an
unmitigated benefit for patients who
would otherwise have to endure the pain
and suffering of acute or terminal medical
conditions. While there is no debate over
the short-term use of opiates, their use
for chronic nonmalignant pain is contro-
versial, and there is growing reluctance
among some physicians to prescribe
them. The problem is that the most
powerful opiate analgesics are also the
most liable to cause abuse and addiction.
Opioids are defined by their actions at
one of the family of opioid G protein-
coupled receptors (GPCRs). There are
four known opioid receptors (mu [m], delta
[d], kappa, and the nociceptin/orphanin
peptide receptor); however, only agonists
at m consistently produce potent anal-
gesia, and drugs activating m (e.g., heroin,
morphine, and oxycodone [OxyContin])
are also the most commonly abused(Koob and Le Moal, 2006; Pasternak,
2011). Despite decades of research,
pharmaceutical companies have been
unable to design opioid ligands that retain
high analgesic potency but with reduced
abuse potential. Furthermore, there are
currently no nonopioid analgesics with
either the broad range of analgesic effi-
cacy or the potency of m agonists. This
lack of progress in new drug development
is particularly daunting in view of the
growth of our understanding of the mech-
anisms of pain and of opioid receptor
function. The inability to uncouple power-
ful analgesia from addictive potential is
a barrier to resolving the current dilemma
about opiate use for chronic pain. In some
ways, dissolving the bond between
potent analgesia and addiction is the
holy grail of pain research. One could
argue that if a drug were found that was
potent across a broad range of painful
conditions, was not addicting, and to
which patients did not develop tolerance,
pain would cease to be a significant
medical problem. Meanwhile, the debate
continues over when and how to use
opiate analgesics.
Those practitioners who favor broader
acceptance of use for chronic nonmalig-
nant pain (e.g., low back pain, neuro-
pathic pain) argue that it is unconscio-
nable to withhold adequate treatment
from any patient complaining of severe
pain, whatever the cause. Furthermore,
they assert that addiction is rare when
opioid analgesics are used appropriately
(e.g., Edlund et al., 2007). Lined up
against them are those who argue that
addiction is a significant risk and isNeuron 69,common among pain patients treated
with opiates. For example, Ballantyne
and LaForge (2007) suggest that long-
term treatment of chronic pain patients
with opiates has contributed to the recent
increase in opiate abuse and addiction.
Unfortunately, the heat of the argument
is sustained by the lack of solid evidence
on either side. Both sides claim the moral
high ground, and an ongoing appeal to
ethics instead of scientific evidence
clouds the essential issues and prevents
consensus on the appropriate use of
opiates in chronic pain.
The decision about long-term opiate
prescribing is further complicated by the
substantial increase in people diverting
and abusing prescription opiate analge-
sics. Figures from the Substance Abuse
and Mental Health Services Administra-
tion (SAMHSA) raise significant red flags;
for example, ‘‘In 2009, an estimated 3.1
million persons aged 12 or older used an
illicit drug for the first time within the
past 12 months.’’ About 17% (500,000
people) initiated illicit drug use with pain
relievers (http://oas.samhsa.gov/NSDUH/
2k9NSDUH/2k9Results.htm). In addition
to their addictive potential, high doses of
potent opiate analgesics cause profound
respiratory depression, the leading cause
of death from these drugs. Because of
this, the problem of opiate diversion has
been dramatically magnified by the
parallel growth of emergency room visits
and deaths due to prescription opiate
overdose (http://oas.samhsa.gov/2k10/
DAWN016/OpioidEdHTML.pdf). The in-
crease in overdose deaths has led to
media headlines and increased socialFebruary 24, 2011 ª2011 Elsevier Inc. 591
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01/06/health/06drugs.html). This in turn
has provoked law enforcement efforts to
disrupt and punish diversion. While the
effectiveness of law enforcement ap-
proaches to this problem is debatable,
these well-meaning efforts further compli-
cate physician decisions. In addition to
concerns about contributing to addiction,
many fear investigation, censure, or even
arrest for prescribing these drugs. Law
enforcement efforts to stem illegal diver-
sion of prescription medications have
very likely shifted the balance in the
medical community back toward under-
prescribing opiates. At this point, it is
unclear whether the increased fear among
physicians of creating an addict or being
investigated by law enforcement has hurt
more individuals, because their pain relief
is inadequate, or has helped more, by
reducing access to a potentially addictive
substance.
How Likely Is Opioid Addiction
in Chronic Pain Patients?
Towhat extent is physician prescription of
pain killers to pain patients responsible for
the epidemic of prescription pain-killer
abuse? The answer is not straightforward.
Prescription opiate abuse is not rare,
but from the same SAMHSA report
mentioned above, statistics suggest that
of those abusing pain relievers, most
(70%) got them illicitly. Less than 20%
got the drugs directly through a prescrip-
tion from a doctor. This suggests that
while diversion and illicit use are real, the
great majority of individuals abusing
opioids (usually young people) are getting
‘‘high’’ by taking grandma’s OxyContin,
stealing them, or buying them from their
friends or relatives and do not get them
by prescription from an MD.
Some illicit users overdose and show
up in emergency rooms or wind up dead
from respiratory depression. Clearly, the
problem is serious from both a social
and medical standpoint. On the other
hand, most people who come to
a physician with a pain complaint have
a valid problem that deserves treatment.
Furthermore, there is evidence to sug-
gest that treating previously drug-naive
chronic pain patients with opioids is asso-
ciatedwith a very low risk of addiction. For
example, Edlund et al. (2007) prospec-
tively studied over 15,000 veterans who592 Neuron 69, February 24, 2011 ª2011 Elswere not on opioids before the study
period. The subjects were started on
opiate analgesics for pain and maintained
on the medications for at least three
months. Only 2% developed opioid
abuse. Although another study indicated
an overall greater incidence of opioid
abuse (6%) in individuals treated for
pain (Pletcher et al., 2006), most of the
abusers had used illicit drugs (mainly
amphetamine) prior to opioid treatment.
Importantly, neither study reported any
cases of opiate addiction, only abuse.
This distinction is important because
substance abuse is much more common
than true addiction, and its definition is
influenced by social, cultural, and legal
factors that are independent of the
medical (or, for that matter, scientifically
addressable) issues. For example, any
recurrent illicit use of a substance that
affects job, school, or interpersonal func-
tion could be considered abuse (e.g.,
habitually taking a roommate’s prescrip-
tion opiate medication). Addiction/depen-
dence is characterized by preoccupation
with obtaining and taking the drug and
a high frequency of use despite obvious
social, medical, legal, and/or economic
harm. The clinical studies referred to
above indicate that opiate addicts and
pain patients are largely separate popula-
tions and that opiate addiction due to
appropriate medical management of
pain is rare. However, the doctor’s deci-
sion for any given patient is still influenced
by the widespread diversion of prescrip-
tion opiate pain killers, because in many
cases it is difficult to know who is faking
a pain complaint to get a prescription.
That said, the person who is lying to get
a drug is already a drug abuser, and so
the prescribing physician is not creating
a new addict or abuser.
The rarity of addiction when opiates are
used to treat pain is counterintuitive,
because the relief of pain itself produces
reward independently by negative rein-
forcement (King et al., 2009). However,
consistent with the clinical evidence,
animal studies using the conditioned
place preference paradigm have demon-
strated that morphine is actually less
rewarding in the presence of ongoing
pain (e.g., see Betourne et al., 2008).
Somehow, the presence of ongoing pain
appears to lower rather than increase
the risk of opiate addiction.evier Inc.Are Chronic Pain Patients Harmed
by Withholding Opiate Pain Killers?
Despite what appears to be a low risk of
addiction in naive, chronic pain patients,
it is reasonable to ask how much harm is
actually done to patients with chronic
pain by withholding opiate analgesics.
Are these drugs effective in this situation,
and if so, how long do they remain effec-
tive? In fact, opiates do produce effective
analgesia when used acutely in patients
with chronic pain (Kalso et al., 2004),
and analgesic effectiveness can be sus-
tained for up to eight weeks. However,
there are no studies confirming their
effectiveness beyond two months, and
the mean pain reduction in the short
term is also modest (Kalso et al., 2004).
There are other reasons to be cautious
when committing a patient to long-term
opioid use. One is that animal studies
suggest that dependence and worsening
of pain are possible with prolonged use
of m agonists. A second potential issue is
analgesic tolerance to opioids. Although
this has not been demonstrated in the
clinical situation, opioid dose escalation
to maintain analgesia is not uncommon.
Furthermore, analgesic tolerance has
been consistently observed in animal
studies (e.g., see Chang et al., 2007). In
addition, at least mild physical depen-
dence can be demonstrated in most
individuals treated with m agonists.
Whether or not physical dependence is
a clinically significant problem in patients
with chronic pain is unknown. However,
animal studies show that opioids can
induce a state of hyperalgesia that could
complicate pain management. Some-
times, hyperalgesia can develop even
when opioid administration is continued
(e.g., see Ossipov et al., 2005; Gardell
et al., 2006), and there is suggestive
evidence that this may occur in pain
patients on daily opiate therapy (Cohen
et al., 2008).
Despite the lack of convincing data for
long-term efficacy and the growing
problem of prescription abuse, many
physicians prescribe opiate analgesics
for patients with chronic nonmalignant
pain. The reasons are complex, but in
the end, alternative approaches to pain
management often fail and, as mentioned
above, opiate analgesics are usually
effective at the onset of treatment. While
short-term benefit is likely, more evidence
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prescribing opiates in the long term for
chronic pain patients. One useful res-
ponse to this uncertainty is to have official
or semiofficial guidelines for opiate use in
chronic nonmalignant pain patients. In
fact, the State of Washington has pub-
lished a set of reasonable patient assess-
ment and care guidelines for the use of
opioids for chronic nonmalignant pain
(http://www.agencymeddirectors.wa.gov/
Files/OpioidGdline.pdf). These include
limiting the dose and amount prescribed;
using urine testing for illicit drug use and
treatment compliance; and asking about
alcohol, tobacco, and drug abuse history
prior to initiating treatment.
If abuse does ensue, there are ways to
minimize the associated harm. The most
serious adverse consequences of opiate
addiction are typically related to (1) the
criminalization of possession and the
cost of buying the drugs (which can lead
to other illegal activity); (2) the uncertain
purity, dose, and potency leading to
overdose; and (3) infections transmitted
by shared needles. The problems of infec-
tion, purity, and uncertain dose are
mitigated if the drugs are obtained by
prescription, taken orally, and used only
by the person who obtains the drug.While
there is always risk of diversion and
overdose, opioid addicts on supervised
opioid maintenance therapy can be freed
of the need to pay for their habit and can
sometimes return to a relatively normal
life. Thus, like chronic pain, opioid
addiction, if not currently curable, can be
managed to minimize harm to the addict
and to society. Interestingly, the two
most widely accepted ‘‘medications’’ for
opiate maintenance therapy are metha-
done (a potent m agonist with very slow
pharmacokinetics) and buprenorphine
(a partial agonist at m), both of which
have been used effectively to treat pain.
If the treatments for pain and addiction
are the same, there is no reason for
the patient to lie about why he or she
wants the opiate prescription. This
openness could lead to an overall
improvement in therapeutic outcomes.
Interestingly, a small but growing number
of physicians are trained in both pain
management and addiction medicine.
This combination of skills may be optimal
for long-term management of pain with
opiate medications.On the Horizon: Exploiting the Cell
Biology of Opioid Receptors to
Enhance Analgesia
Although chronic pain does respond at
least temporarily to opiate drugs, as
mentioned above, there is both animal
and human evidence that tolerance and
dependence limit their effectiveness.
Consequently, for many chronic pain
patients, the treatment options are
limited. The public is entitled to ask,
what have we gotten in return for the
millions we have spent on pain research?
Canwe dissolve the bond between potent
pain relief and drug dependence/abuse?
There are some glimmers of hope. The
binding of different ligands for the same
receptor may activate distinct down-
stream signaling pathways in different
cells, and some of these signaling path-
ways activate compensatory mecha-
nisms that oppose the initial agonist effect
(Pasternak, 2011). For example, following
ligand binding, signaling is reduced in
many GPCRs, including the m receptor,
by removal of the receptor from the
plasma membrane through internaliza-
tion. This requires phosphorylation of the
receptor byGPCR kinases and interaction
with b-arrestin (von Zastrow, 2010). Some
m ligands, e.g. morphine, activate G
protein signaling but are typically much
less effective in inducing b-arrestin
signaling and receptor internalization. In
this situation in some cells, morphine
continues to signal, triggering compensa-
tory cellular mechanisms that oppose key
cellular actions of the m agonist that
regulate membrane excitability. Further-
more, when morphine is subsequently
removed by washout or through adminis-
tration of an antagonist, the compensa-
tory processes dominate, producing
actions opposite to those originally
triggered by morphine and manifesting
as increased responsiveness to noxious
stimuli. Consistent with this idea, mice
with a genetically modified m that can
be efficiently internalized by morphine
binding show dramatically reduced toler-
ance and dependence (Kim et al., 2008).
This raises the possibility that drugs tar-
geted to specific signaling pathways
might alleviate pain symptoms yet lack
the addictive properties of the current
opioid analgesics.
Another promising line of research is
the study of m/d interactions. AlthoughNeuron 69,opiate analgesics initially act primarily at
m, repeated administration of a m agonist
can activate a d-mediated opposing
process. d knockout mice do not develop
morphine tolerance, and d antagonists
can prevent morphine tolerance. Syn-
thetic bivalent molecules with a m agonist
at one end and a d antagonist at the other
show enhanced analgesia and reduced
tolerance (Daniels et al., 2005). Impor-
tantly, examination of a series of such
bivalent compounds with increasing
separation of the m agonist and d antago-
nist moieties demonstrated that theymust
be separated by a critical distance for
optimal efficacy. This suggests that
the bivalent compounds work best
when the two receptors are in spatial
proximity. Perhaps most exciting, the
study authors report that the bivalent
compounds retain analgesic potency but
are significantly less rewarding (Lenard
et al., 2007).
In summary, although opiate analge-
sics are potent for a variety of time-
limited painful conditions, the duration
of their efficacy has only been estab-
lished for up to two months. Animal
studies indicate that tolerance and
dependence are common with repeated
opioid use, and both animal and human
studies indicate that long-term adminis-
tration of opiate analgesics can actually
worsen pain. Because of this, significant
caution should be exercised in initiating
therapy for patients with chronic nonma-
lignant pain. On the other hand, although
the potential is there, addiction is actually
quite rare in patients treated appropri-
ately for pain. In fact, the presence of
pain appears to provide a protective
action against the rewarding effects of
opiates. The real problem for the treating
physician is that diversion of prescription
pain killers for recreational use is
growing, yet for many patients with
chronic nonmalignant pain, there is
currently no better treatment alternative
than opiate analgesics. The scientific
challenge is to design a drug that retains
high analgesic potency with reduced
potential for tolerance, dependence,
and addiction. The good news is that
studies of membrane receptor traf-
ficking, signaling, and interaction and in
the chemistry of bifunctional molecules
suggest that this long-standing goal
may yet be achieved.February 24, 2011 ª2011 Elsevier Inc. 593
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